The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

Published:2021-09-23 Issue:10 Volume:22 Page:1294-1305
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Tomalka Jeffrey Alan,Pelletier Adam Nicolas,Fourati Slim^ORCID,Latif Muhammad Bilal,Sharma Ashish,Furr Kathryn,Carlson Kevin,Lifton Michelle^ORCID,Gonzalez Ana,Wilkinson Peter,Franchini Genoveffa^ORCID,Parks Robert,Letvin Norman,Yates Nicole,Seaton Kelly^ORCID,Tomaras Georgia,Tartaglia Jim,Robb Merlin L.^ORCID,Michael Nelson L.,Koup Richard,Haynes Barton,Santra Sampa^ORCID,Sekaly Rafick Pierre

Funder

Foundation for the National Institutes of Health

U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41590-021-01026-9.pdf

Reference50 articles.

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).

2. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671 (2006).

3. Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665 (2005).

4. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).

5. Gottardo, R. et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 8, e75665 (2013).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine;Cell Reports;2024-07

2. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial;PLOS Medicine;2024-03-19

3. Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects;Viruses;2024-02-27

4. Expression of the SARS-CoV-2 Receptor ACE2 and Protease TMPRSS2 in Ocular Hypertension Eyes of Nonhuman Primate and Human;Current Eye Research;2024-01-11

5. Identification of novel prognostic autoantibodies in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high‐throughput antigen microarray;Cancer;2023-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3